Orchestra BioMed Holdings, Inc.

OBIOReported to SECin USCIK 0001814114Filings at SEC EDGAR

No score on this page, by design. Everything here is a fact from a public U.S. register: insider filings at the SEC (Form 4), lobbying filings under the Lobbying Disclosure Act, trades reported by members of Congress under the STOCK Act, and fund holdings in 13F filings. Our scores, percentiles and signals run on the Dutch register only, because that is the only register the model has been validated on.

This page is free to read, and it stops after 5 rows. Those are the 5 most recent Form 4 lines at this company, out of 14. Reading the whole list, and the full version of each filer's page, is part of the subscription. What that costs is on the pricing page. Already subscribed? Sign in and this page opens in full.

The most recent filings

Most recent filing first: every line of every Form 4 at this company that passed our review, the same lines as on the register. Reported is the day the filing reached the SEC, usually within two business days of the trade. Amounts are in U.S. dollars, as the form states them.

5 of 14
Form 4 lines at Orchestra BioMed Holdings, Inc., most recent filing first
Filed byTypeValueReportedFiled byValueTypeSharesReported
Hochman David PSee RemarksAdministrative$19,0743,283 sharesSep 11, 2026Hochman David PSee Remarks$19,074Admin · Sep 11Administrative3,283Sep 11, 2026
Hochman David PSee RemarksAdministrative$19,0743,283 sharesSep 11, 2026Hochman David PSee Remarks$19,074Admin · Sep 11Administrative3,283Sep 11, 2026
Hochman David PSee RemarksOpen-market buy$47,90010,000 sharesSep 8, 2026Hochman David PSee Remarks$47,900Buy · Sep 8Open-market buy10,000Sep 8, 2026
Sherman DarrenSee RemarksOpen-market sell$74,10015,000 sharesSep 2, 2026Sherman DarrenSee Remarks$74,100Sell · Sep 2Open-market sell15,000Sep 2, 2026
Taylor Andrew LawrenceChief Financial OfficerAdministrative$16,1803,076 sharesAug 28, 2026Taylor Andrew LawrenceChief Financial Officer$16,180Admin · Aug 28Administrative3,076Aug 28, 2026